Skip to main content
Premium Trial:

Request an Annual Quote

Genome Technology All Stars Are In (Vodka-Tonic, Please)

BOSTON, Oct. 4 - Forgive us if our voices are a bit hoarse.

Half an hour before the booze floodgates opened at Genome Technology magazine's annual All Stars awards bash last night, the winners were announced.

Person of the Year: Howard Cash of Gene Codes


Company or Institute of the Year: Affymetrix


Product of the Year: PerkinElmer's AcycloPrime-FP


Most Visionary Dealmaker: Jonathan Rothberg of CuraGen


Database Doyen/Doyenne: Jim Kent of the Universityof California, Santa Cruz


Most Prolific in Proteomics: Ruedi Aebersold, Institute for Systems Biology


Most Innovative in Bioinformatics: Martin Leach of CuraGen


High Performance Computing's Highest Guru: Shankar Subramaniam of the San Diego Supercomputing Center


Most Masterful in Microarrays: Stephen Fodor of Affymetrix


Most Outstanding in Sequencing Technology: Elaine Mardis of WashingtonUniversity

Nearly 3,000 readers of Genome Technology magazine, GenomeWeb's sister publication, voted by online ballot this summer. Winners in each of the 10 categories received the GT All-Star trophy, and four finalists in each category were recognized with GT All-Stars certificates.

The awards were presented by Meredith Salisbury, managing editor of Genome Technology, and Peter Coggins, president of life sciences at PerkinElmer, which sponsored the GT All-Stars. Gene Logic, Hewlett-Packard, and Iobion cosponsored the awards.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.